Please assess the completion status of the following clinical trial:

Trial Title: Directly Observed Therapy for HCV in Chennai, India

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing/able to provide consent~2. Age ≥ 18~3. Chronic HCV (HCV RNA positive)~4. Resident of Chennai and can provide locator information~5. If co-infected with HIV, must have CD4 (Cluster of Differentation 4) \> 350 cells/mm3 and either: 1) ART naïve or 2) if on ART be on a tenofovir-containing regimen. If a participant's CD4 drops below 350 cells/μl (threshold for treatment in India), will have to initiate a tenofovir-containing regimen (current standard of care).~6. Participants must have the following at screening:~   1. Alanine Aminotransferase (ALT) ≤ 10 x the upper limit of normal (ULN)~  2. Aspartate Aminotransferase (AST) ≤ 10 x ULN~  3. Hemoglobin ≥ 12 g/dl for males and 11 g/dl for females~  4. International normalized ratio (INR) ≤ 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR~  5. Albumin ≥ 3 g/dl~  6. Direct bilirubin ≤ 1.5 x ULN~  7. Creatinine clearance ≥ 60 ml/min (Cockgroft-Gault Equation)~  8. Alpha fetoprotein \< 50 ng/ml~  9. Absolute neutrophil count (ANC) ≥ 1,500/μL~  10. Platelets ≥ 90,000/μL~  11. Thyroid stimulating hormone (TSH) ≤ ULN~7. A female subject is eligible if it is confirmed that she is:~   1. Not pregnant or nursing~  2. Of non-childbearing potential (i.e., women who have had hysterectomy, have both ovaries removed or medically documented ovarian failure, or are postmenopausal women \> 50 years of age with cessation (for ≥12 months) of previously occurring menses~  3. Of childbearing potential and negative urine pregnancy test prior to randomization and agree to one of the following from 3 weeks prior to Baseline/Day 1 until 6 months after the last dose of RBV.~      * Complete abstinence from intercourse.~   Or~   • Consistent use of approved methods of birth control in addition to a male partner who correctly uses a condom from 3 weeks prior to Baseline/Day 1 until 6 months after the last dose of RBV.~8. Male participants must agree to consistently and correctly use a condom. If their female partner is of childbearing potential, their partner must agree to use one of the study approved non-hormonal methods of birth control or a hormone-containing contraceptive, from the date of screening until 7 months after their last dose of RBV~9. Male participants must agree to refrain from sperm donation for at least 7 months after the last dose of RBV.~10. Of generally good health as determined by the investigator.~11. Able to comply with the dosing instructions for study drug administration and willing to complete the study schedule of assessments.~Exclusion Criteria:~1. Pregnant/nursing female or male with pregnant/nursing female partner.~2. Current or prior history of clinical hepatic decompensation (e.g., ascites, encephalopathy or variceal hemorrhage, MELD\<12)~3. Prior hepatitis C treatment~4. Infection with hepatitis B virus~5. Chronic use of systematically administered immunosuppressive agents (e.g., prednisone equivalent \>10 mg/day)~6. Use of any prohibited concomitant medications within 28 days of the Baseline/Day 1 visit.~7. Contraindications to RBV therapy or PEG/RBV~8. Known hypersensitivity to RBV or PEG, the metabolites or formulation excipients~9. Additional exclusion criteria related to Aim 1 regimen~   1. Pre-existing significant psychiatric condition(s) including severe depression, severe bipolar disorder and schizophrenia. Other psychiatric disorders are permitted if the condition is well controlled with a stable treatment regimen for ≥ 1 year from screening.~  2. Presence of autoimmune disorders (e.g., systemic lupus erythematosus, rheumatoid arthritis, sarcoidosis).~  3. History of clinical significant retinal disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF+PEG+RBV (Type: ACTIVE_COMPARATOR): Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks
- SOF+RBV (Type: ACTIVE_COMPARATOR): Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).